Interview with the Director and CEO: CEL-SCI Corporation (NYSEAMERICAN:CVM)
Geert Kersten is Director and Chief Executive Officer of CEL-SCI Corporation. Mr. Kersten has served in his current leadership role at CEL-SCI since 1995. Mr. Kersten has been with CEL-SCI from the early days of its inception since 1987. He has been involved in the pioneering field of cancer immunotherapy for almost three decades and has successfully steered CEL-SCI through many challenging cycles in the biotechnology industry. Mr. Kersten also provides CEL-SCI with significant expertise in the fields of finance and law, and has a unique vision of how the company's Multikine product will change the way cancer is treated. Prior to CEL-SCI, Mr. Kersten worked at the law firm of Finley & Kumble and worked at Source Capital, an investment banking firm located in McLean, Virginia. He is a native of Germany, graduated from Millfield School in England and completed his studies in the U.S. Mr. Kersten completed his undergraduate degree in accounting, received an MBA from George Washington University and a law degree — J.D. — from American University in Washington, D.C. Mr. Kersten is also the inventor of a patent on the potential use of Multikine in managing cholesterol. Profile
Word count: 2,829
TWST: Could you just briefly describe the company?
Mr. Kersten: We want to do our best to actually cure cancer patients. We believe the key to